Inclusion Criteria:

- Histologically or cytologically confirmed transitional cell cancer of the urothelium
or bladder

- Metastatic disease

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 2.0 cm by
conventional techniques OR ≥ 1.0 cm by spiral CT scan

- No known brain metastases

- ECOG performance status 0−2

- Life expectancy ≥ 12 weeks

- Platelet count ≥ 100,000/mm^3

- WBC ≥ 3,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Bilirubin normal

- AST and ALT ≤ 2.5 times upper limit of normal (ULN)

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- PT/INR/PTT ≤ 1.2 times ULN

- No proteinuria > 1+ on two consecutive dipsticks measured ≥ 1 week apart

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to pazopanib hydrochloride or other agents used in the study

- No condition that impairs the ability to swallow and retain pazopanib hydrochloride
tablets, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No uncontrolled illness that would limit compliance with study therapy including,
but not limited to, any of the following:

- Ongoing or active infection

- Psychiatric illness or social situations

- No QTc prolongation (defined as a QTc interval ≥ 480 msecs) or other significant ECG
abnormalities (e.g., frequent ventricular ectopy, evidence of ongoing myocardial
ischemia)

- No other conditions, including any of the following:

- Serious or non-healing wound, ulcer, or bone fracture

- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
within the past 28 days

- Cerebrovascular accident within the past 6 months

- Myocardial infarction, cardiac arrhythmia, or admission for unstable angina
within the past 12 weeks

- Venous thrombosis within the past 12 weeks

- New York Heart Association (NYHA) class III or IV heart failure

- Asymptomatic NYHA class II heart failure on treatment allowed

- No other active second malignancy other than non-melanoma skin cancer

- Patients are not considered to have an active malignancy if they have completed
anti-cancer therapy and are considered by their physician to be ≤ 30% risk of
relapse

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
and recovered

- At least 4 weeks since prior radiotherapy

- Prior palliative radiotherapy to metastatic lesions allowed provided there is ≥ 1
measurable and/or evaluable lesion(s) that has not been irradiated

- At least 4 weeks since prior surgery

- One prior chemotherapy regimen for metastatic urothelial or bladder cancer

- More than 12 weeks since prior cardiac angioplasty or stenting

- Prior adjuvant or neoadjuvant therapy allowed

- No prior experimental treatment for metastatic disease

- No other prior or concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent CYP2C9 substrates

- No other concurrent anticancer agents or therapies

- No concurrent medications that are associated with a risk of QTc prolongation and/or
Torsades de Pointes